Scemblix
Novartis Sees Steady Q3 Pluvicto Sales Growth as it Readies to Triple Eligible Population in 2025
Premium
The Swiss drugmaker is gearing up to meet a surge in patient demand for the radiopharmaceutical if the FDA approves it in an earlier-line prostate cancer setting.
Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts.
Novartis' Scemblix Bests Gleevec, Second-Generation TKIs in Frontline CML
Major molecular response data reported at ASCO could change the treatment paradigm in newly diagnosed Philadelphia chromosome-positive CML.
The drugmaker will seek regulatory approval for Scemblix in first-line Ph-positive CML and other precision drugs in the coming months.
The radioligand therapy hit roadblocks with supply constraints in early 2023, but a new manufacturing facility has since helped Novartis get back on track.